133 Cost-effectiveness of dry-powder mannitol for inhalation as an add-on to best supportive care (BSC) in the treatment of adult cystic fibrosis (CF) patients in Ireland

Objectives Despite advances in BSC, European CF patients still experience reduced life-expectancy, impaired lung function (FEV1 ) and frequent pulmonary exacerbations requiring hospital admission. Airway clearance is critical to improve outcomes but options remain limited. In pooled analysis of 2 Ph...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cystic fibrosis 2015-06, Vol.14, p.S91-S91
Main Authors: Schwenkglenks, M, Toward, T.J, Dooley, B, Burns, R.M, Adams, E.J, Van Stiphout, J
Format: Article
Language:English
Subjects:
Pulmonary/Respiratory
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives Despite advances in BSC, European CF patients still experience reduced life-expectancy, impaired lung function (FEV1 ) and frequent pulmonary exacerbations requiring hospital admission. Airway clearance is critical to improve outcomes but options remain limited. In pooled analysis of 2 Phase III RCTs substantiating the EU adult license, inhaled dry-powder mannitol (Bronchitol®) improved FEV1 (p
ISSN:1569-1993
1873-5010
DOI:10.1016/S1569-1993(15)30310-6